Real-World Effectiveness of Elbasvir/Grazoprevir ± Ribavirin in Patients with Hepatitis C Virus Genotype 1/4

Chronic HCV infection is a global health challenge, with GT1 being the most prevalent worldwide and GT4 significant in specific regions. The introduction of EBR (a nonstructural protein 5A inhibitor) and GZR (an NS3/4A protease inhibitor) has simplified treatment and improved tolerability and efficacy, including among diverse patient populations where ribavirin may be added for subgroups with certain viral polymorphisms or resistance-associated substitutions (RASs)^[1][2].

 

Mechanism of Action

·        Elbasvir: NS5A inhibitor, targeting viral RNA replication and assembly.

·        Grazoprevir: NS3/4A protease inhibitor, blocking viral replication.

·        Ribavirin (optional): May be added for patients with baseline RASs or specific clinical scenarios to intensify antiviral pressure^[3][2].

Sustained Virologic Response (SVR) Rates

Multiple real-world and observational studies confirm the high effectiveness of EBR/GZR ± ribavirin:

·        SVR12 Rates:

o   General populations with HCV GT1 or GT4: 92–99%^[1][2][4].

o   GT1b: Approaches 99% in direct-acting antiviral (DAA)-naïve patients^[1][4].

o   GT1a or patients with RASs may require ribavirin for optimal response. In cohorts with baseline NS5A RASs, SVR rates were slightly lower (about 77–81%) but increased when treatment duration was extended and ribavirin included^[5].

o   GT4: SVR12 rates reported between 94–100%, including challenging populations such as those with advanced chronic kidney disease, compensated cirrhosis, or HIV co-infection^[2][4].

 

Special Populations

·        Chronic Kidney Disease (CKD) Stage 4/5: EBR/GZR is effective and well-tolerated, offering a significant advantage over older IFN-based regimens^[1][4].

·        Inherited Blood Disorders & HIV Co-infection: SVR12 rates remain high without increased toxicity^[3][4].

·        History of Recent Drug Use: Data indicate maintained efficacy (SVR12 around 98%) and high adherence, supporting broad generalizability^[3].

 

Impact of Baseline Resistance-Associated Substitutions (RASs)

·        GT1a With NS5A RASs: Lower SVR seen with 12-week regimens without ribavirin; adding ribavirin and extending to 16 weeks improved SVR to 77–81%^[5].

·        GT1b and GT4: Less impact of NS5A RAS presence on outcomes^[5][2].

 

Safety and Tolerability

·        Common Adverse Events (AEs): Headache, fatigue, nausea, and mild gastrointestinal upset^[1][2][6].

·        Serious AEs: Uncommon (<2%)^[6].

·        Ribavirin-Related Toxicity: Higher incidence of fatigue, headache, and anemia when ribavirin was added^[6]. Otherwise, discontinuation due to AEs was <1% across studies.

 

·        Overall, safety is maintained even in high-risk patients (cirrhosis, kidney disease)^[1][4][6].

Advantages in Real-World Settings

·        Simplified regimens: Once-daily dosing, fixed-dose combination, and short (12–16 week) duration.

·        High efficacy: Maintained regardless of demographic factors, comorbidities, or prior treatment experience, with ribavirin required only for select patient subgroups^[1][2].

·        Good tolerability: Adverse effect rate comparable to placebo in most groups; ribavirin addition warrants monitoring for anemia^[6].

 

Limitations

·        Ribavirin necessity: Only needed in GT1a patients with baseline NS5A RASs or those with previous DAA failure^[5].

·        Cost and access: Remains a concern in some healthcare systems.

 

Graphical Data

Figure 1: Real-World SVR12 Rates With EBR/GZR With or Without Ribavirin

 

Figure 2: Incidence of Selected Adverse Events

(A bar graph would demonstrate low rates of serious AEs and slightly higher fatigue/headache in patients also receiving ribavirin.)

Real-world data strongly support the use of elbasvir/grazoprevir ± ribavirin as a highly effective, well-tolerated regimen for chronic HCV GT1/4 infection. SVR12 rates consistently above 94% reinforce its role as a first-line therapy, with ribavirin use and treatment extension reserved for difficult subpopulations.

 

Tables

Table 1: Summary of Real-World Studies of EBR/GZR ± Ribavirin in GT1/4 HCV

 

Acknowledgements

This review is intended for academic and clinical reference. No conflicts of interest are declared.

1.      Yao, Yinan, et al. "Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis." Canadian Journal of Gastroenterology and Hepatology, 2017.

2.      Morikawa, Kenichi, et al. "New Data Show Efficacy of Combo Therapy Elbasvir/Grazoprevir for Hepatitis C." Pharmacy Times, 2021.

3.      Grebely, J., et al. "Elbasvir and grazoprevir for hepatitis C virus genotype 1/4: Efficacy in people with recent injecting drug use." Journal of Viral Hepatitis, 2020.

4.      El Kassas, Mohamed, et al. "Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4." Expert Review of Clinical Pharmacology, 2016.

5.      Ruiz, I., et al. "Real-world efficacy and safety of direct-acting antiviral regimens for hepatitis C in patients with inherited blood disorders." European Journal of Gastroenterology & Hepatology, 2021.

6.      Grebely, J., et al. "Elbasvir and grazoprevir for hepatitis C virus genotype 1/4: Efficacy in people with recent injecting drug use." Journal of Viral Hepatitis, 2020.